Alnylam Pharmaceuticals (ALNY) PT Raised to $203 at Morgan Stanley After Oxlumo Approved for PH1
Tweet Send to a Friend
Morgan Stanley analyst David Lebowitz raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $203.00 (from $200.00) after Oxlumo ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
